Equity Overview
Price & Market Data
Price: $2.13
Daily Change: $0.00 / 0.00%
Daily Range: $1.85 - $2.42
Market Cap: $382,809,472
Daily Volume: 2,140,287
Performance Metrics
1 Week: 3.40%
1 Month: -12.35%
3 Months: 114.1%
6 Months: 326.2%
1 Year: 353.5%
YTD: 114.1%
Company Details
Employees: 78
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoimmune diseases; and CNTY-101, an allogeneic, iPSC-derived CAR-iNK cell therapy with six precision gene edits engineered to express CD19 CAR, with Allo-Evasion 1.0 edits designed for the treatment of CD19 for B-cell mediated autoimmune diseases. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.